International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension

Hypertension Clinical Trial

— EnligHTN III  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01836146
• Other study ID #: 1202
• Status: Completed
• Phase: N/A
• Start date: April 2013
• Est. completion date: September 2015

Study information

• Verified date: February 2019
• Source: Abbott Medical Devices
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this First-in-Human Clinical investigation is to evaluate the safety and performance of the St. Jude Medical EnligHTN™ Generation 2 Renal Denervation System for the treatment of patients with drug-resistant uncontrolled hypertension.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: September 2015
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subject is = 18 and = 80 years of age at time of consent

• Subject must be able and willing to provide written informed consent

• Subject must be able and willing to comply with the required follow-up schedule

• Subject has office Systolic Blood Pressure = 160 mmHg at confirmatory visit

• Subject has a daytime mean Systolic Ambulatory Blood Pressure > 135 mmHg during the two week screening period

• Subject has an office Systolic Blood Pressure that remains =160 mmHg despite the stable use of =3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic or subject was previously on diuretic but documented to be diuretic intolerant, for a minimum of 14 days prior to the procedure and with an expectation to maintain for a minimum of 180 days post procedure.

Exclusion Criteria:

• Subject has significant renovascular abnormalities such as renal artery stenosis > 30% in either renal artery

• Subject has undergone prior renal angioplasty, renal denervation, indwelling renal stents, and/or abdominal aortic stent grafts

• Subject has hemodynamically significant valvular heart disease as determined by the Study Investigator

• Subject has a life expectancy less than 12 months, as determined by a Study Investigator

• Subject is participating in another clinical study which has the potential to impact their hypertension management (pharmaceutical/device/homeopathic)

• Subject is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods

• Subject has active systemic infection

• Subject has renal arteries with diameter(s) < 4 mm in diameter or <20 mm in length

• Subject has an estimated Glomerular Filtrate Rate (eGFR) <45 mL/min per 1.73 m2 using the Modified Diet in Renal Disease (MDRD) formula

• Subject has Diabetes Mellitus Type I

• Subject has multiple main renal arteries in either kidney

• Subject has an identified secondary cause of hypertension (for example, including, but not limited to, Polycystic kidney disease, Cushing's syndrome, Aldosteronism)

• Subject has evidence of significant abdominal aortic aneurysm (defined as maximum diameter of >4 cm)

• Subject has had a myocardial infarction, unstable angina pectoris or cerebrovascular accident less than 180 days prior to enrollment

• Subject is expected to have cardiovascular intervention within the next 180 days

• Subject has a condition which would interfere with the accurate interpretation of the study objectives including but not limited to a large arm diameter that is unable to accommodate the blood pressure cuff or arrhythmia that interferes with automatic pulse sensing.

Related Conditions & MeSH terms

• Hypertension
• Renal Denervation

Intervention

Device:
• EnligHTN™ Renal Artery Ablation Catheter

Locations

Country	Name	City	State
Australia	St Andrews Hospital	Adelaide	South Australia
Australia	St. Vincent's Hospital Melbourne	Fizroy	Victoria
Australia	Monash Heart/Southern Health	Melbourne	Victoria
Australia	Royal Melbourne Hospital	Melbourne	Victoria
New Zealand	Auckland City Hospital	Auckland
New Zealand	Dunedin Hospital	Dunedin

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Devices

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Objective	To characterize the rate of serious procedural and device related adverse events from date of procedure through 6 months post procedure, as adjudicated by the Clinical Events Committee (CEC).	6 months
Primary	Performance objective	To characterize the reduction of office Systolic Blood Pressure at 6 months post procedure as compared to baseline.	6 months
Secondary	Change in Ambulatory Blood Pressure	Characterization of the change in Ambulatory Blood Pressure parameters over time as compared to baseline	1 month, 3 month, 6 month, 12 month, 18 month, 2 years
Secondary	New renal artery stenosis or aneurysm at the site of ablation	Characterization of renovascular safety as measured by new renal artery stenosis or aneurysm at the site of ablation over time as compared to baseline	1 month, 3 month, 6 month, 12 month, 18 month, 2 years
Secondary	Renal Function Change	Characterization of renal function change over time as compared to baseline as measured by changes in: eGFR, serum creatinine and cystatin C	1 month, 3 month, 6 month, 12 month, 18 month, 2 years